Topiramate, pseudotumor cerebri, weight-loss and glaucoma: An ophthalmologic perspective

Patrick Alore, Walter Jay, Mícheál Macken*

*Corresponding author for this work

Research output: Contribution to journalShort surveypeer-review

25 Scopus citations


Approved for the treatment of epilepsy and migraine prophylaxis, topiramate also acts as a carbonic anhydrase inhibitor implying a potential role in the treatment of pseudotumor cerebri (PTC). Topiramate has a propensity to cause anorexia with consequent weight loss, which alone may be curative in PTC. Prescribers must be aware of several reported cases of acute secondary angle-closure glaucoma reported in patients treated with topiramate.

Original languageEnglish (US)
Pages (from-to)15-17
Number of pages3
JournalSeminars in Ophthalmology
Issue number1
StatePublished - Jan 1 2006


  • Glaucoma
  • Pseudotumor cerebri
  • Topiramate
  • Weight loss

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Topiramate, pseudotumor cerebri, weight-loss and glaucoma: An ophthalmologic perspective'. Together they form a unique fingerprint.

Cite this